Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-20

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

NCT03184805

Coronary Artery Disease

TERMINATED NA

The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass

NCT01268917

Coronary Artery Disease Off-pump Coronary Artery Bypass Aspirin

UNKNOWN PHASE3

Perioperative Aspirin Response in Patients Undergoing Vascular Surgery

NCT03587324

Vascular Surgery Patient With PAD / Carotid Stenosis

COMPLETED NA

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

NCT02797548

Antiplatelet Drugs

COMPLETED PHASE4

Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery

NCT02209909

Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PCI with coronary stent implantation is performed for a huge number of patients with coronary artery disease. Approximately 20% of these patients undergo non-cardiac surgery within three years after PCI. However, there is a scarcity of clinical evidence regarding the efficacy of perioperative aspirin continuation on cardiovascular events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antiplatelet Agents Perioperative Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aspirin Continuation

perioperative aspirin continuation

Group Type EXPERIMENTAL

Aspirin

Intervention Type DRUG

perioperative aspirin continuation

Interruption of Antiplatelet Therapy

Interruption of aspirin 5-7 days before surgery

Group Type ACTIVE_COMPARATOR

Aspirin interruption

Intervention Type DRUG

Aspirin interruption 5-7 days before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aspirin

perioperative aspirin continuation

Intervention Type DRUG

Aspirin interruption

Aspirin interruption 5-7 days before surgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aspirin (drug) Aspirin interruption (drug)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a history of coronary stenting and scheduled for abdominal surgery
* Patients on a single antiplatelet agent

Exclusion Criteria

* Patients on dual antiplatelet therapy (DAPT)
* Patients on anticoagulation therapy
* Patients with a history of stent thrombosis
* Patients with CHADS2 score \>= 5
* Patients at extremely high risk of bleeding and unable to continue preoperative aspirin
* Patients incapable of consent, including those under 20 years of age
* Other patients for whom either discontinuation or continuation of antiplatelet agents is deemed inappropriate by the attending physician

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No